These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25904831)

  • 1. The future of hepatitis C virus therapeutics.
    Kwo PY
    Gastroenterol Hepatol (N Y); 2014 Jul; 10(7):433-5. PubMed ID: 25904831
    [No Abstract]   [Full Text] [Related]  

  • 2. [Some considerations about hepatitus C virus].
    Perez E; Cruz J; Henriquez L; Baez J
    Arch Domin Pediatr; 1996; 32(2):57-62. PubMed ID: 12348030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and application of an in vitro model for screening anti-hepatitis B virus therapeutics.
    Lampertico P; Malter JS; Gerber MA
    Hepatology; 1991 Mar; 13(3):422-6. PubMed ID: 1705531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis.
    Dey D; Banerjee M
    J Clin Transl Hepatol; 2016 Sep; 4(3):248-257. PubMed ID: 27777893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chimeric GB virus B with 5' nontranslated RNA sequence from hepatitis C virus causes hepatitis in tamarins.
    Rijnbrand R; Yang Y; Beales L; Bodola F; Goettge K; Cohen L; Lanford RE; Lemon SM; Martin A
    Hepatology; 2005 May; 41(5):986-94. PubMed ID: 15793797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus therapy: What's the future holding for us?
    Manzoor S; Saalim M; Imran M; Resham S; Ashraf J
    World J Gastroenterol; 2015 Nov; 21(44):12558-75. PubMed ID: 26640332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.
    Guo JT; Guo H
    Antiviral Res; 2015 Oct; 122():91-100. PubMed ID: 26272257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus RNA tests: performance attributes and their impact on clinical utility.
    Comanor L; Hendricks D
    Expert Rev Mol Diagn; 2003 Nov; 3(6):689-702. PubMed ID: 14628898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleic acid vaccines for hepatitis B and C virus.
    Karimkhanilouyi S; Ghorbian S
    Infect Genet Evol; 2019 Nov; 75():103968. PubMed ID: 31325609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A CLINICAL STUDY ON THE USE OF IMMUNE GLOBULIN PROPHYLAXIS IN PATIENTS RECEIVING BLOOD AND-OR PLASMA TRANSFUSIONS.
    DAWSON D
    Curr Ther Res Clin Exp; 1965 Mar; 7():184-7. PubMed ID: 14265005
    [No Abstract]   [Full Text] [Related]  

  • 11. Links between Human LINE-1 Retrotransposons and Hepatitis Virus-Related Hepatocellular Carcinoma.
    Honda T
    Front Chem; 2016; 4():21. PubMed ID: 27242996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants in the Ig Variable Domain of Human HAVCR1 (TIM-1) Are Required To Enhance Hepatitis C Virus Entry.
    Kachko A; Costafreda MI; Zubkova I; Jacques J; Takeda K; Wells F; Kaplan G; Major ME
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29321304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HepaRG cell line: a valuable in vitro tool for hepatitis virus infection studies.
    Ceelen L; Lieveld M; Forsyth R; Vinken M
    Hepatol Int; 2013 Jun; 7(2):394-9. PubMed ID: 26201773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention: Hepatitis viruses, human T-cell leukemia viruses, herpesviruses, and Epstein-Barr virus.
    Mui UN; Haley CT; Vangipuram R; Tyring SK
    J Am Acad Dermatol; 2019 Jul; 81(1):23-41. PubMed ID: 30502415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications.
    Li W; Urban S
    J Hepatol; 2016 Apr; 64(1 Suppl):S32-S40. PubMed ID: 27084034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach.
    Deuffic-Burban S; Mathurin P; Rosa I; Bouvier AM; Cannesson A; Mourad A; Canva V; Louvet A; Deltenre P; Boleslawski E; Truant S; Pruvot FR; Dharancy S
    Dig Liver Dis; 2014 Feb; 46(2):157-63. PubMed ID: 24119483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathogenesis of hepatitis C virus].
    Moriishi K; Matsuura Y
    Uirusu; 2007 Dec; 57(2):141-9. PubMed ID: 18357752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C therapy before and after liver transplantation.
    Terrault NA
    Liver Transpl; 2008 Oct; 14 Suppl 2():S58-66. PubMed ID: 18825697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C Virus: Evading the Intracellular Innate Immunity.
    Ferreira AR; Ramos B; Nunes A; Ribeiro D
    J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32183176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics.
    Wald O; Weiss ID; Galun E; Peled A
    Cytokine; 2007 Jul; 39(1):50-62. PubMed ID: 17629707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.